Hyperion Therapeutics Inc

Pharmaceutical Product Development is one of the leading contract research organizations in the world. The organization offers discovery, development and post-approval services, as well as compound partnering programs. It specializes in providing research services in the areas of general medicine, dermatology, hematology, oncology, immunology, ophthalmology, urology and pediatrics. Pharmaceutical Product Development also offers preclinical evaluation, data management, safety reporting, patient recruitment and pharmacology consulting solutions. The organization operates offices in more than 30 countries and employs over 10,500 professionals. Its clients include pharmaceutical, biotechnology, medical device, academic and government organizations. Pharmaceutical Product Development operates bioanalytical labs and utilizes advanced therapeutic technologies.

Altri Biotherapeutics is a preclinical-stage pharmaceutical company based in Richmond, VA, specializing in the development of therapeutic monoclonal antibodies (mAbs) targeting the insulin-like growth factor (IGF) signaling system for cancer treatment. With a focus on triple-negative breast cancer (TNBC) and plans to expand into other metastatic and invasive cancers, Altri has licensed patents from Virginia Commonwealth University to advance its innovative therapeutic approaches. The company's lead candidate, ALT101, has demonstrated significant antitumor and antimetastatic activity in preclinical studies, particularly against TNBC, which disproportionately affects certain demographics and currently has limited treatment options. Altri aims to progress its therapeutic candidates toward IND filing and Phase III clinical trials, addressing critical unmet medical needs in cancer treatment. Generated from the website